Key facts
- Notable investors include Shenzhen Yifeng Investment Management Enterprise.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Essight
- ·The full record, as it builds
Funding rounds
No funding rounds for Essight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Essight
Developer of drugs designed intended for biotechnology companies, clinical research institutions, and pharmaceutical developers. The company's products mainly focus on optimizing the core technology platform, core pipeline molecules, and investigator-initiated trials, clinical trial work of the T-Cell receptor drug pipeline, providing customers with innovative and efficient products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Website
- essight.com/
- Ownership
- Privately Held (backing)
Essight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Essight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Essight in its N-PORT filings yet. We sweep new filings monthly.